The Experts below are selected from a list of 12159 Experts worldwide ranked by ideXlab platform
Redwan Moqbel - One of the best experts on this subject based on the ideXlab platform.
-
The Eosinophil as a therapeutic target in Asthma: beginning of the end, or end of the beginning?
Current opinion in pharmacology, 2003Co-Authors: Darryl J. Adamko, S.o. Odemuyiwa, Redwan MoqbelAbstract:A major goal in Asthma therapy is to reduce or prevent the inflammatory response associated with bronchial hyperresponsiveness, reversible airway obstruction and airway remodelling. However, because of the complex nature of the disease, a single target for such an ideal therapeutic approach remains elusive. To ensure a more rational design of anti-Asthma drugs, recent investigations have attempted to elucidate the roles of inflammatory cellular components in Asthma. Such studies have shown that Eosinophilic infiltration is a prominent feature in the pathophysiology of Asthma. Nonetheless, the role of the Eosinophil in Asthma has been questioned following recent human studies investigating the efficacy of a novel therapeutic strategy targeted at Eosinophils.
-
A report from the international Eosinophil Society: Eosinophils in a tug of war.
The Journal of allergy and clinical immunology, 2001Co-Authors: Paige Lacy, Peter F. Weller, Redwan MoqbelAbstract:The international Eosinophil Symposium in Banff was a timely gathering of leading experts to discuss the precise role of Eosinophils in allergic Asthma. The meeting followed hard on the heels of a report suggesting that Eosinophils might be redundant in late-phase responses in Asthma, inasmuch as treatment of Asthmatic patients with humanized anti-IL-5 in clinical trials failed to modify bronchial hyperresponsiveness. Mouse models of allergic Asthma were also cited for failing to show a consistent proinflammatory role for the Eosinophil in Asthma. Presentations at this meeting included a reevaluation of murine models of Asthma, which exhibit substantial differences from human disease. The inability of murine Eosinophils to degranulate either in vivo or in vitro was shown to present a major obstacle in Asthma research; this is in sharp contrast to human Eosinophils, which readily degranulate in response to stimuli. Degranulation from Eosinophils was proposed to be a crucial event in human airway hyperresponsiveness. Major advances were presented in the understanding of molecular and intracellular pathways regulating Eosinophil priming, activation, and mediator secretion. Recruitment and activation of Eosinophils might be regulated by other immunoregulatory agents as well as IL-5, including eotaxin. Future clinical trials might benefit from focusing on dual inhibition of IL-5 and eotaxin to ensure the removal of the effects of activated Eosinophils from the body.
Douglas S. Robinson - One of the best experts on this subject based on the ideXlab platform.
-
A role for Eosinophils in airway remodelling in Asthma
Trends in immunology, 2004Co-Authors: A. Barry Kay, Simon Phipps, Douglas S. RobinsonAbstract:Over the years, the role of the Eosinophil in Asthma and allergic processes has been disputed. Recent human experiments using a humanised monoclonal antibody to interleukin-5 (IL-5), and animal studies involving specific IL-5 gene deletion, indicates that Eosinophils might control downstream repair and remodelling processes. Eosinophils are a rich source of fibrogenic factors, particularly transforming growth factor-β (TGF-β), the latent form of which is activated by epithelial-cell expression of the intergin α v β 6 . The emerging role for the Eosinophil in airway remodelling might be important in future anti-Asthma strategies. However, more effective Eosinophil-depleting agents than anti-IL-5 are required before the definitive role of this cell type in Asthma airway pathophysiology can be established.
A. Barry Kay - One of the best experts on this subject based on the ideXlab platform.
-
A role for Eosinophils in airway remodelling in Asthma
Trends in immunology, 2004Co-Authors: A. Barry Kay, Simon Phipps, Douglas S. RobinsonAbstract:Over the years, the role of the Eosinophil in Asthma and allergic processes has been disputed. Recent human experiments using a humanised monoclonal antibody to interleukin-5 (IL-5), and animal studies involving specific IL-5 gene deletion, indicates that Eosinophils might control downstream repair and remodelling processes. Eosinophils are a rich source of fibrogenic factors, particularly transforming growth factor-β (TGF-β), the latent form of which is activated by epithelial-cell expression of the intergin α v β 6 . The emerging role for the Eosinophil in airway remodelling might be important in future anti-Asthma strategies. However, more effective Eosinophil-depleting agents than anti-IL-5 are required before the definitive role of this cell type in Asthma airway pathophysiology can be established.
Darryl J. Adamko - One of the best experts on this subject based on the ideXlab platform.
-
The Eosinophil as a therapeutic target in Asthma: beginning of the end, or end of the beginning?
Current opinion in pharmacology, 2003Co-Authors: Darryl J. Adamko, S.o. Odemuyiwa, Redwan MoqbelAbstract:A major goal in Asthma therapy is to reduce or prevent the inflammatory response associated with bronchial hyperresponsiveness, reversible airway obstruction and airway remodelling. However, because of the complex nature of the disease, a single target for such an ideal therapeutic approach remains elusive. To ensure a more rational design of anti-Asthma drugs, recent investigations have attempted to elucidate the roles of inflammatory cellular components in Asthma. Such studies have shown that Eosinophilic infiltration is a prominent feature in the pathophysiology of Asthma. Nonetheless, the role of the Eosinophil in Asthma has been questioned following recent human studies investigating the efficacy of a novel therapeutic strategy targeted at Eosinophils.
Martin K. Church - One of the best experts on this subject based on the ideXlab platform.
-
The role of the Eosinophil in Asthma.
The American review of respiratory disease, 1991Co-Authors: S. T. Holgate, William R. Roche, Martin K. ChurchAbstract:After the initial description of the histochemical characteristics of the Eosinophil by Paul Erhlich in 1879 (1), recognition that this cell has associations with Asthma was soon appreciated. Some of the earlier histopathologic descriptions of bronchial tissue from patients who had died from Asthma contain vivid descriptions of the heavy Eosinophil infiltrate of the airway walls, and for many years clinicians have also recognized the presence of free Eosinophils in the sputum of patients with Asthma, particularly during acute exacerbations (2). The characteristic Charcot-Leyden crystals frequently observed in Eosinophilenriched sputum represent a crystallized form of the enzyme lysolecithinase derived from degenerated Eosinophils (3). Finally, the presence of increased numbers of Eosinophils in the peripheral blood of patients with both atopic and nonatopic (intrinsic) Asthma (4) provides further evidence implicating these cells in the pathogenesis of this form of disordered airway function.